- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05429476
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Posterior circulation stroke accounts for 20-25% of all ischemic strokes, with an annual adjusted incidence of 18 per 100,000 person-years. Compared with anterior circulation stroke, posterior circulation stroke is less studied and has poor neurological outcomes, which requires attention. Intravenous thrombolytic therapy has greatly improved the rate of recanalization and reperfusion in patients with acute ischemic stroke, increased the proportion of patients with good prognosis, and reduced mortality. Guidelines recommend intravenous thrombolysis within 4.5 hours of onset or awakening in patients with ischemic stroke. However, the proportion of posterior circulation stroke is low or unreported in most randomized controlled trials, such as 5% of patients in the NINDS study, so it may be inappropriate to apply the results of these trials directly to patients with posterior circulation ischemic stroke.
Multiple studies have also shown a lower risk of post-circulation bleeding complications compared to pre-circulation stroke. A meta-analysis of patients with posterior circulation ischemic stroke (11.9% of posterior circulation stroke) showed that posterior circulation stroke had a lower risk of intracranial hemorrhage due to intravenous thrombolysis, half the risk of anterior circulation stroke, and a higher 3-month good functional outcome. The lower risk of hemorrhagic transformation in posterior circulation stroke is due to the greater tolerance of the posterior circulation area to ischemic injury, possibly due to a greater proportion of white matter and arterial collaterals, especially in the brainstem. In addition, the smaller infarct size of posterior circulation stroke compared with anterior circulation stroke also reduced the risk of bleeding in these patients.
Therefore, the purpose of this study was to investigate whether patients with posterior circulation stroke with onset or discovery time of 4.5-24 hours could benefit from intravenous thrombolysis in the Chinese population.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Jiashan, Zhejiang, China
- Recruiting
- The First People's Hospital of Jiashan
-
Contact:
- Tinghuan Wang
- Phone Number: 18867650389
- Email: tinghuanwang@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients presented with clinical signs of acute ischemic stroke between 4.5 and 24 hours of stroke onset or awakening with stroke (if between 4.5 and 24 hours from the midpoint of sleep).
- Patient's age is > 18 years (or as per local requirements).
- NIHSS ≥ 1.
- Patients with post circulation ASPECT score ≥ 7.
- Patients meet at least one of the below criteria: post circulation stroke considered by experienced clinicians, or infarction of posterior circulation confirmed by MRI, or the vascular examination indicates that there are symptomatic stenosis or occlusion of large posterior circulation vessels, or the perfusion image indicates that there are symptomatic hypoperfusion changes in the posterior circulation area.
- Pre-stroke mRS score < 2.
- Patients do not receive endovascular treatment at patients' and treating clinician's discretion
- Patient, family member or legally responsible person depending on local ethics requirements has given informed consent.
Exclusion Criteria:
- Contraindication for alteplase.
- A life expectancy of less than three months.
- The judgment is left to the discretion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Alteplase with standard therapy
Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
|
Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour Other Names: Actilyse Activase tPA r-tPA
Other Names:
|
NO_INTERVENTION: Standard therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
independent recovery assessed by ratio of modefied Rankin Scale (mRS) score of 0-2 (%) at 90 days
Time Frame: 90 days
|
mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
recovery assessed by modefied Rankin Scale (mRS) score at 90 days
Time Frame: 90 days
|
mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome
|
90 days
|
excellent recovery assessed by the ratio of modefied Rankin Scale (mRS) score of 0-1 (%) at 90 days
Time Frame: 90 days
|
mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome
|
90 days
|
Change in ≥ 8 National Institutes of Health Stroke Scale (NIHSS) points or reaching ≤ 1 on this scale at 24 hours
Time Frame: 24 hours
|
NIHSS: minimum value = 0, maximum value = 42, and higher scores mean severer symptoms
|
24 hours
|
Change in ≥ 8 National Institutes of Health Stroke Scale (NIHSS) points or reaching ≤ 1 on this scale at 7 days
Time Frame: 7 days
|
NIHSS: minimum value = 0, maximum value = 42, and higher scores mean severer symptoms
|
7 days
|
independent recovery assessed by ratio of modefied Rankin Scale (mRS) score of 0-2 (%) at 1 year
Time Frame: 1 year
|
mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome
|
1 year
|
Symptomatic Intracerebral Hemorrhage (sICH) at 24 hours
Time Frame: 24 hours
|
Symptomatic hemorrhage defined by SITS-MOST criteria: type 2 parenchymal hematoma associated with ≥4 point increase in NIHSS
|
24 hours
|
Symptomatic Intracerebral Hemorrhage (sICH) at 7 days
Time Frame: 7 days
|
Symptomatic hemorrhage defined by SITS-MOST criteria: type 2 parenchymal hematoma associated with ≥4 point increase in NIHSS
|
7 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EXPECTS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Acute Ischemic
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Tissue Plasminogen Activator (Alteplase)
-
Thomas Jefferson UniversityGenentech, Inc.Unknown
-
Xuanwu Hospital, BeijingRecruitingAcute Ischemic Stroke | Arterial Thrombosis | Posterior Circulation Brain InfarctionChina
-
The University of Texas Health Science Center,...Genentech, Inc.CompletedIschemic StrokeUnited States
-
Washington University School of MedicineMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedVenous Thrombosis | Deep Vein Thrombosis | Postphlebitic Syndrome | Venous Thromboembolism | Post Thrombotic SyndromeUnited States
-
Hospital Clinic of BarcelonaFundacion Clinic per a la Recerca Biomédica; Fundació La Marató de TV3Completed
-
Penumbra Inc.Completed
-
Mazandaran University of Medical SciencesCompletedMortality | Stroke, Acute | Thrombolytic Therapy | AlteplaseIran, Islamic Republic of
-
Neuroscience Trials AustraliaMelbourne Health; University of Melbourne; Commonwealth Scientific and Industrial... and other collaboratorsCompletedStrokeAustralia, Finland, New Zealand
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Neuroscience Trials AustraliaChina Medical University HospitalCompleted